Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
By V. Stearns, Michael D. Johnson, J. Rae, A. Morocho, A. Novielli, P. Bhargava, D. Hayes, Z. Desta, D. Flockhart. Journal of the National Cancer Institute, 2003
876 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Pharmacology
View Paper: https://www.semanticscholar.org/paper/2a7957f89bc424d2a2c9e0bad7b7b8f97979ec26
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Mechanisms of tamoxifen resistance. (2004, background): “In addition, women with a variant CYP2D6 allele receiving tamoxifen also had lower plasma concentrations of the metabolite (Stearns et al. 2003).”
- Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 (2004, methodology): “There is evidence that endoxifen is much more abundant in plasma of breast cancer patients than 4-hydroxyTAM (Lien et al., 1990; Stearns et al., 2003).”